Latest news with #Jewik
Associated Press
28-03-2025
- Business
- Associated Press
TMDX REMINDER: Suffer Losses on TransMedics Group? Contact BFA Law by April 15 Class Action Deadline
NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in TransMedics, you are encouraged to obtain additional information by visiting Investors have until April 15, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased TransMedics securities. The case is pending in the U.S. District Court for the District of Massachusetts and is captioned Jewik v. TransMedics Group, Inc. et al, No. 25-cv-10385. Why was TransMedics Sued for Fraud? TransMedics is a commercial-stage medical technology company. The Company's 'Organ Care System' ('OCS') is a medical device that keeps donor organs viable before transplant by replicating many aspects of the organ's natural living and functioning environment outside of the human body. The complaint alleges that TransMedics misrepresented that its business was driven by kickbacks, fraudulent overbilling, and coercive tactics. The complaint further alleges that the company misrepresented that it engaged in unsafe practices involving OCS, hid safety issues, and generally lacked safety oversight. The Stock Declines as the Truth is Revealed On February 21, 2024, U.S. Representative and member of the House Committee on Oversight and Accountability Paul Gosar issued a letter accusing the Company of misconduct including overcharging for OCS and misappropriating corporate resources. This news allegedly caused the price of TransMedics stock to decline approximately 4% over two trading days, from $86.99 per share on February 21, 2024 to $83.14 per share on February 23, 2024. On December 2, 2024, TransMedics announced the resignation of its CFO from that role and narrowed its financial outlook for 2024. Then, on January 10, 2025, Scorpion Capital issued a research report explaining that TransMedics's growth was fueled by an anti-competitive scheme that included kickbacks to medical providers to use the company's products and that TransMedics further boosted growth by operating an organ trafficking scheme, engaged in widespread billing fraud, and promoted off-label use. The publication of the Scorpion Capital report caused the price of TransMedics stock to decline an additional 5%, from $72.55 per share on January 8, 2025 to $68.81 per share on January 10, 2025. Click here for more information: . What Can You Do? If you invested in TransMedics you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact: 212-789-3619 Why Bleichmar Fonti & Auld LLP? Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs' Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
Associated Press
17-03-2025
- Business
- Associated Press
TransMedics Group (TMDX) Plunges Amidst Allegations of Fraud, Organ Trafficking
SAN FRANCISCO, March 17, 2025 (GLOBE NEWSWIRE) -- A class-action lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX), a medical technology company specializing in organ transplant therapy, alleging that the company and certain executives engaged in fraudulent practices and concealed safety issues. The suit, captioned Jewik v. TransMedics Group, Inc., No. 25-cv-10385 (D. Mass.), represents investors who purchased or acquired TransMedics securities between February 28, 2023, and January 10, 2025. Hagens Berman is investigating the alleged claims and urges investors who purchased TransMedics shares and suffered substantial losses to submit your losses now. Lead Plaintiff Deadline: Apr. 15, 2025 Visit: 844-916-0895 The TransMedics Group (TMDX) Class Action The complaint alleges that TransMedics made false and misleading statements, while failing to disclose crucial information. Specifically, the suit contends that TransMedics used kickbacks, fraudulent overbilling, and coercive tactics to boost business and revenue. Furthermore, it alleges that the company engaged in unsafe practices, concealed safety problems, and generally lacked adequate safety oversight, exposing TransMedics to heightened regulatory risk. The lawsuit details two events that allegedly disclosed defendants' misconduct to the market that adversely impacted the company's stock price. On February 21, 2024, Representative Paul Gosar issued a letter accusing TransMedics of misappropriating corporate resources. The allegations were subsequently reported by The Daily Caller on February 22, 2024, causing a drop in TransMedics' stock price, according to the complaint. More recently, on January 10, 2025, activist short seller Scorpion Capital released a report leveling accusations against TransMedics, including overbilling hospitals, coercing customers into using specific services, and providing patients with organs rejected by reputable physicians via doctors allegedly paid by TransMedics. This report further depressed the company's stock price, the lawsuit claims. Prominent investor rights firm Hagens Berman Sobol Shapiro LLP is probing whether TransMedics misled investors regarding its sales practices. 'We are looking into claims that TransMedics engaged in improper billing practices and concealed safety issues. These allegations, if true, could have significant implications for both patients and investors,' said Reed Kathrein, the Hagens Berman partner leading the investigation. If you invested in TransMedics and have substantial losses, or have knowledge that may assist the firm's investigation, submit your losses now » If you'd like more information and answers to frequently asked questions about the TransMedics case and our investigation, read more » Whistleblowers: Persons with non-public information regarding TransMedics should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected]. Contact:
Associated Press
10-03-2025
- Business
- Associated Press
TMDX CLASS ACTION ALERT: Lose Money when TransMedics Group, Inc. Plummeted 30%? Contact BFA Law about the Class Action Lawsuit
NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in TransMedics, you are encouraged to obtain additional information by visiting Investors have until April 15, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased TransMedics securities. The case is pending in the U.S. District Court for the District of Massachusetts and is captioned Jewik v. TransMedics Group, Inc. et al, No. 25-cv-10385. Why was TransMedics Sued for Fraud? TransMedics is a commercial-stage medical technology company. The Company's 'Organ Care System' ('OCS') is a medical device that keeps donor organs viable before transplant by replicating many aspects of the organ's natural living and functioning environment outside of the human body. The complaint alleges that TransMedics misrepresented that its business was driven by kickbacks, fraudulent overbilling, and coercive tactics. The complaint further alleges that the company misrepresented that it engaged in unsafe practices involving OCS, hid safety issues, and generally lacked safety oversight. The Stock Declines as the Truth is Revealed On February 21, 2024, U.S. Representative and member of the House Committee on Oversight and Accountability Paul Gosar issued a letter accusing the Company of misconduct including overcharging for OCS and misappropriating corporate resources. This news allegedly caused the price of TransMedics stock to decline approximately 4% over two trading days, from $86.99 per share on February 21, 2024 to $83.14 per share on February 23, 2024. On December 2, 2024, TransMedics announced the resignation of its CFO from that role and narrowed its financial outlook for 2024. Then, on January 10, 2025, Scorpion Capital issued a research report explaining that TransMedics's growth was fueled by an anti-competitive scheme that included kickbacks to medical providers to use the company's products and that TransMedics further boosted growth by operating an organ trafficking scheme, engaged in widespread billing fraud, and promoted off-label use. The publication of the Scorpion Capital report caused the price of TransMedics stock to decline an additional 5%, from $72.55 per share on January 8, 2025 to $68.81 per share on January 10, 2025. Click here for more information: . What Can You Do? If you invested in TransMedics you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact: 212-789-3619 Why Bleichmar Fonti & Auld LLP? Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs' Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
Associated Press
04-03-2025
- Business
- Associated Press
TMDX CLASS ACTION: Lose Money on TransMedics Group, Inc.? Investors are Notified to Contact BFA Law before April 15 Class Action Deadline (NASDAQ:TMDX)
NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in TransMedics, you are encouraged to obtain additional information by visiting Investors have until April 15, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased TransMedics securities. The case is pending in the U.S. District Court for the District of Massachusetts and is captioned Jewik v. TransMedics Group, Inc. et al, No. 25-cv-10385. Why was TransMedics Sued for Fraud? TransMedics is a commercial-stage medical technology company. The Company's 'Organ Care System' ('OCS') is a medical device that keeps donor organs viable before transplant by replicating many aspects of the organ's natural living and functioning environment outside of the human body. The complaint alleges that TransMedics misrepresented that its business was driven by kickbacks, fraudulent overbilling, and coercive tactics. The complaint further alleges that the company misrepresented that it engaged in unsafe practices involving OCS, hid safety issues, and generally lacked safety oversight. The Stock Declines as the Truth is Revealed On February 21, 2024, U.S. Representative and member of the House Committee on Oversight and Accountability Paul Gosar issued a letter accusing the Company of misconduct including overcharging for OCS and misappropriating corporate resources. This news allegedly caused the price of TransMedics stock to decline approximately 4% over two trading days, from $86.99 per share on February 21, 2024 to $83.14 per share on February 23, 2024. On December 2, 2024, TransMedics announced the resignation of its CFO from that role and narrowed its financial outlook for 2024. Then, on January 10, 2025, Scorpion Capital issued a research report explaining that TransMedics's growth was fueled by an anti-competitive scheme that included kickbacks to medical providers to use the company's products and that TransMedics further boosted growth by operating an organ trafficking scheme, engaged in widespread billing fraud, and promoted off-label use. The publication of the Scorpion Capital report caused the price of TransMedics stock to decline an additional 5%, from $72.55 per share on January 8, 2025 to $68.81 per share on January 10, 2025. Click here for more information: . What Can You Do? If you invested in TransMedics you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact: 212-789-3619 Why Bleichmar Fonti & Auld LLP? Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs' Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
Associated Press
02-03-2025
- Business
- Associated Press
TMDX REMINDER: TransMedics Group, Inc. was Sued for Securities Fraud; Investors are Alerted to Contact BFA Law before April 15 Deadline (NASDAQ:TMDX)
NEW YORK, March 02, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in TransMedics, you are encouraged to obtain additional information by visiting Investors have until April 15, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased TransMedics securities. The case is pending in the U.S. District Court for the District of Massachusetts and is captioned Jewik v. TransMedics Group, Inc. et al, No. 25-cv-10385. Why was TransMedics Sued for Fraud? TransMedics is a commercial-stage medical technology company. The Company's 'Organ Care System' ('OCS') is a medical device that keeps donor organs viable before transplant by replicating many aspects of the organ's natural living and functioning environment outside of the human body. The complaint alleges that TransMedics misrepresented that its business was driven by kickbacks, fraudulent overbilling, and coercive tactics. The complaint further alleges that the company misrepresented that it engaged in unsafe practices involving OCS, hid safety issues, and generally lacked safety oversight. The Stock Declines as the Truth is Revealed On February 21, 2024, U.S. Representative and member of the House Committee on Oversight and Accountability Paul Gosar issued a letter accusing the Company of misconduct including overcharging for OCS and misappropriating corporate resources. This news allegedly caused the price of TransMedics stock to decline approximately 4% over two trading days, from $86.99 per share on February 21, 2024 to $83.14 per share on February 23, 2024. On December 2, 2024, TransMedics announced the resignation of its CFO from that role and narrowed its financial outlook for 2024. Then, on January 10, 2025, Scorpion Capital issued a research report explaining that TransMedics's growth was fueled by an anti-competitive scheme that included kickbacks to medical providers to use the company's products and that TransMedics further boosted growth by operating an organ trafficking scheme, engaged in widespread billing fraud, and promoted off-label use. The publication of the Scorpion Capital report caused the price of TransMedics stock to decline an additional 5%, from $72.55 per share on January 8, 2025 to $68.81 per share on January 10, 2025. Click here for more information: . What Can You Do? If you invested in TransMedics you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Or contact: 212-789-3619 Why Bleichmar Fonti & Auld LLP? Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs' Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
